FDA Approves DIFLUPREDNATE OPHTHALMIC — Sandoz Inc

Sandoz Inc. announced the approval of difluprednate ophthalmic (NDA022212) on June 23, 2008, a move that introduces a potent ophthalmic corticosteroid option to the market and intensifies price competition in the anti-inflammatory eye drop sector. This potential influx of a branded generic is poised to challenge the dominance of high-cost corticosteroids, likely pressuring pricing for existing ophthalmic products in the post-launch landscape.